Monitor for Pacira's next steps, including any petition for rehearing or certiorari, and for the District Court's recalculation of interest on remand. The resumption of royalty payments could pressure EXPAREL margins.
Drug in focus
PCRX drug pipeline →EXPAREL
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed since 2011.
- Next catalyst
- None dated
What to watchEXPAREL is a mature, approved product with no upcoming binary drug catalyst. The stock trades at the $36.50 Viatris acquisition price, so the near-term move depends entirely on deal closing (expected by end of 2026). Watch for the Ninth Circuit royalty ruling's impact on EXPAREL margins and any updates on the tender offer's regulatory clearance.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $36.46entry
- T+1 · 19h ago +0.05%α +1.97% · $36.48
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Ninth Circuit reversed in part the District Court's judgment in Pacira's royalty dispute with RDF, ruling that Pacira owes royalties on EXPAREL made using its 200-liter manufacturing process. The case is remanded to recalculate pre-judgment interest on the 45-liter portion. Pacira had previously received a $28.3 million cash payment from RDF, which may now be partially at risk.
Key Facts
- On November 6, 2026, the Ninth Circuit reversed the District Court's judgment in part, holding that Pacira owes royalties on EXPAREL manufactured using its 200-liter process.
- The Court of Appeals directed the District Court to enter judgment in favor of RDF on the 200-liter claim.
- The matter was remanded to recalculate pre-judgment interest RDF owes on the 45-liter EXPAREL portion.
- Pacira had previously received a $28.3 million cash payment from RDF in July 2025, representing $23.1 million in royalties paid under protest plus $5.2 million in statutory interest.
- Pacira is evaluating its legal options and intends to vigorously defend its rights.
- The low single-digit royalty on EXPAREL sales had been eliminated after the District Court's April 2025 judgment.
Financial Impact
Pacira may be required to resume paying a low single-digit royalty on EXPAREL sales made using the 200-liter process, and could be at risk of repaying some or all of the $28.3 million cash received from RDF. The exact financial impact is not quantified in the filing.
Risk Factors
- Pacira may be required to repay a portion of the $28.3 million cash received from RDF.
- Resumption of royalty payments on 200-liter EXPAREL sales could reduce gross margins.
- Further appeals or litigation could prolong uncertainty and legal costs.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-043437 |
| Document: 0001140361-26-043437-index-headers.html | 0001140361-26-043437 |
| Document: 0001140361-26-043437-index.html | 0001140361-26-043437 |
| Document: 0001140361-26-043437.txt | 0001140361-26-043437 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Viewing Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers